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Many Alzheimer’s disease (AD) genes including Apolipoprotein E (APOE) are found to be expressed 
in blood-derived macrophages and thus may alter blood protein levels. We measured 91 neuro-
proteins in plasma from 316 participants of the Rotterdam Study (incident AD = 161) using Proximity 
Extension Ligation assay. We studied the association of plasma proteins with AD in the overall sample 
and stratified by APOE. Findings from the Rotterdam study were replicated in 186 AD patients of the 
BioFINDER study. We further evaluated the correlation of these protein biomarkers with total tau 
(t-tau), phosphorylated tau (p-tau) and amyloid-beta (Aβ) 42 levels in cerebrospinal fluid (CSF) in the 
Amsterdam Dementia Cohort (N = 441). Finally, we conducted a genome-wide association study 
(GWAS) to identify the genetic variants determining the blood levels of AD-associated proteins. Plasma 
levels of the proteins, CDH6 (β = 0.638, P = 3.33 × 10−4) and HAGH (β = 0.481, P = 7.20 × 10−4), 
were significantly elevated in APOE ε4 carrier AD patients. The findings in the Rotterdam Study were 
replicated in the BioFINDER study for both CDH6 (β = 1.365, P = 3.97 × 10−3) and HAGH proteins 
(β = 0.506, P = 9.31 × 10−7) when comparing cases and controls in APOE ε4 carriers. In the CSF, CDH6 
levels were positively correlated with t-tau and p-tau in the total sample as well as in APOE ε4 stratum 
(P < 1 × 10−3). The HAGH protein was not detected in CSF. GWAS of plasma CDH6 protein levels showed 
significant association with a cis-regulatory locus (rs111283466, P = 1.92 × 10−9). CDH6 protein is 
implicated in cell adhesion and synaptogenesis while HAGH protein is related to the oxidative stress 
pathway. Our findings suggest that these pathways may be altered during presymptomatic AD and that 
CDH6 and HAGH may be new blood-based biomarkers.
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Apolipoprotein E (APOE) is the most common genetic risk factor for Alzheimer’s disease (AD)1,2 and an impor-
tant driver of the lifetime risk for AD3,4. APOE interacts with other common genetic determinants of AD2,5, 
suggesting an interaction with specific protein pathways. Despite two decades of research, the role of APOE 
in determining the risk of AD is far from being understood6. The IMI ADAPTED (The Alzheimer’s Disease 
Apolipoprotein Pathology for Treatment Elucidation and Development) is an Innovative Medicine Initiative 
(IMI) that aims to improve the understanding about the role of APOE gene in AD.
AD pathology is characterized by the extracellular deposition of amyloid-beta (Aβ)-42 and intracellular accu-
mulation of phosphorylated tau in the brain. Cerebrospinal fluid (CSF) levels of Aβ-42, phosphorylated (p-tau) 
and total tau (t-tau) are well-established biomarkers of the central nervous system and brain AD pathology7. 
However, there is a growing evidence for a relation between other pathologies and AD, such as vascular pathol-
ogy8. For example, studies integrating epidemiological and vascular research showed that vascular pathology 
may affect brain function and increase the risk of AD9. APOE and many of the novel genes implicated in AD are 
expressed in monocytes/macrophages10–12 in the blood, and thus these genes may alter the protein signatures 
in blood. There is also a growing body of evidence indicating that Aβ may disrupt the cerebral microcircula-
tion regulation13–15, endothelial function16,17, and brain perivascular macrophages function18. Thus, protein and 
metabolite homeostasis in blood may also be altered as a consequence of (early) amyloid pathology. Indeed, there 
is an increasing interest in the relation between protein levels in plasma and AD during presymptomatic stages 
of AD19. Multiple studies have investigated the association of a range of proteins with AD in plasma, but few have 
addressed the effect of APOE19–25. Furthermore, there is lack of investigations connecting molecular signatures of 
AD in blood to neuropathological AD markers in CSF.
Advances in high-throughput omics technologies have allowed the detection and quantification of several 
classes of plasma-based biomolecular compounds including circulating metabolites and proteins26. In the present 
study, we aimed to identify altered levels of proteins in the circulation of presymptomatic AD patients in the over-
all population and among various genetic risk groups based on the APOE gene, with a view to obtaining insights 
into molecular signatures in the circulation. To this end, we have examined the association of neurology relevant 
proteins in a prospective population-based, the Rotterdam Study. Proteins associated with AD were further tested 
for replication in the BioFINDER study. Next, we conducted a genome-wide association study to find the genetic 
variants determining the blood levels of AD-associated proteins. Finally, we studied the association of the protein 
consistently associated with AD to amyloid and tau levels in CSF in the Amsterdam Dementia Cohort (ADC).
Results
Association of plasma proteins with AD. Detailed results of overall and APOE stratified associ-
ation analysis of proteins with AD are provided in Table 1 and Fig. 1. No significantly associated protein to 
AD was identified in the overall analysis at an FDR < 0.05. Overall, there is a tendency that protein levels are 
more likely increased (positive effect size, β) than decreased (negative effect size, β) in AD patients that carry 
the APOE ε4 allele (Fig. 1a,b) and those homozygous for APOE ε3 allele (Fig. 1c) but not for APOE ε2 patients 
(Fig. 1d). In APOE stratified discovery analysis, we observed that levels of CDH6 (β = 0.638, P = 3.33 × 10−4, 
FDR = 0.030) and HAGH (β = 0.481, P = 7.20 × 10−4, FDR = 0.033) were significantly increased in AD patients 
who carry the APOE ε4 allele (see Table 1). Both CDH6 (β = 0.624, P = 5.52 × 10−4, FDR = 0.030) and HAGH 
(β = 0.491, P = 6.62 × 10−4, FDR = 0.030) proteins remained significantly associated with AD even after adjusting 
for other covariates in model 2 (Supplementary Table 1). In the replication analysis in the BioFINDER study 
(Table 2), plasma levels of CDH6 and HAGH were significantly associated with AD in the overall sample (CDH6: 
β = 1.212, P = 5.18 × 10−4; HAGH: β = 0.631, P = 7.56 × 10−15) as well as in APOE ε4 carriers (CDH6: β = 1.365, 
P = 3.97 × 10−3; HAGH: β = 0.506, P = 9.31 × 10−7) but not in APOE ε2 carriers. Plasma levels of HAGH protein 
were also associated with AD in APOE ε33 carriers (β = 0.739, P = 3.76 × 10−7) but in this subgroup no associa-
tion was seen with CDH6.
Figure 2 shows that the APOE genotype modifies the association between proteins and AD based on 
nominal statistical significance. In discovery analysis, eight additional proteins (TN-R, Beta-NGF, MDGA1, 
JAM-B, CD200, LXN, PDGF-R-alpha, and LAIR-2) were also positively associated with AD APOE ε4 carriers 
(β > 0.107, P < 0.05), but they did not survive multiple testing. In the APOE2 stratum, the levels of two pro-
teins including SMPD1 and VWC2 were reduced in AD cases compared to the APOE genotype matched con-
trols (Supplementary Fig. 1). In APOE33 stratum, PRTG, CNTN5 and NCAN proteins, that do not emerge in 
the APOE4 or APOE2 stratum (see Fig. 2), showed suggestive associations but did not survive multiple testing 
(β > 0.193, P < 2.57 × 10−2). Both CDH6 (β = 0.202, P = 1.79 × 10−1) and HAGH (β = −0.018, P = 8.42 × 10−1) 
did not show association with AD in APOE33 carriers while HAGH showed nominal association in APOE ε2 
carriers (β = 0.482, P = 4.25 × 10−2) (See Table 1).
Sensitivity analyses. Sensitivity analyses were performed in the Rotterdam Study to test the robustness of 
our findings. In the first sensitivity analysis (Supplementary Table 2), we adjusted for follow-up time, taking into 
account that some cases or controls may die of other diseases. This analysis showed that levels of both HAGH 
(β = 0.477, P = 6.47 × 10−4) and CDH6 (β = 0.661, P = 1.48 × 10−4) proteins were significantly increased in AD 
patients compared to controls in APOE ε4 carriers. In the second sensitivity analysis, we only analyzed protein 
that were assessed directly (non-imputed data). Similarly, the association of HAGH and CDH6 proteins with AD 
remained significant in APOE ε4 carriers when analyzing non-imputed proteomics data (Supplementary Table 3). 
Last but not least, we performed a formal interaction test to evaluate the interaction of APOE with each of the 
91 proteins (Supplementary Table 4). Only three of 91 proteins showed interaction with APOE (P-value < 0.05) 
including HAGH (βinteraction = 0.414, Pinteraction = 1.70 × 10−2), G-CSF (βinteraction = 0.276, Pinteraction = 2.78 × 10−2) 
and CRTAM (βinteraction = −0.221, Pinteraction = 3.77 × 10−2). Except, HAGH other two proteins (G-CSF, CRTAM) 
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did not show association with AD in any of the analyzed APOE stratum (P-value > 0.05). For CDH6, the test for 
interaction was not significant (βinteraction = 0.078, Pinteraction = 7.23 × 10−1).
Association of CDH6 and HAGH protein levels with Aβ−42, p-tau, and t-tau in CSF. Among the 
two proteins that were associated to the future risk of AD, CDH6 and HAGH, the latter was not detected in the 
CSF in >90% of the subjects in ADC cohort. CSF CDH6 protein levels were not associated with AD (β = 0.329, 
SE = 0.220, P = 0.136) in the overall as well as in APOE stratified analysis (P > 0.114; see Supplementary Table 5). 
However, multiple regression analysis adjusted for age and sex revealed a significant association of CDH6 CSF 
levels with both p-tau (β = 23.2, SE = 3.4, P = 3.48 × 10−11) and t-tau (β = 207.4, SE = 36.4, P = 2.40 × 10−8) when 
pooling AD patients and controls (Table 3 and Fig. 3). In the APOE stratified analysis, levels of CDH6 were signif-
icantly associated with p-tau and t-tau levels but not with Aβ−42 levels in CSF in three APOE strata (see Table 3). 
When stratifying by case-control status (Supplementary Table 6), CDH6 levels were significantly associated with 
p-tau and t-tau levels in both cases and controls. In controls, also Aβ−42 was positively associated with CDH6 
(P < 1 × 10−3; see Supplementary Table 6).
Association of proteins with APOE. Next, we associated the APOE genotype to the protein levels signifi-
cantly associated with AD (CDH6 and HAGH). Results of the association of protein levels with APOE genotypes 
are provided in Supplementary Table 7 and Supplementary Fig. 2. In the overall sample, CDH6 protein levels were 
increased in the APOE ε4 carriers compared to APOE ε2 carriers (β = 0.163, P = 3.79 × 10−3). In controls, levels 
of CDH6 protein were decreased (β = −0.131, P = 0.026) in APOE ε2 carriers compared to APOE 33 carriers. 
In the controls, levels of HAGH were decreased in the APOE ε4 (β = −0.192, P = 0.028) and APOE ε2 carriers 
(β = −0.214, P = 0.042) compared to APOE 33 carriers.
Genome-wide association study (GWAS). The GWAS was conducted to determine the genetic drivers of 
the CDH6 and HAGH protein levels (Supplementary Figs. 3a and 4 respectively). We identified 13 genome-wide 
significant cis protein quantitative trait loci (pQTLs) located at 5p13.3 locus of chromosome 5 for CDH6 protein 
Uniprot id Annotation
Effect size 




P55285 CDH6 0.334 1.397 0.106 1.78 × 10−3 0.162
Q2VWP7 PRTG 0.286 1.331 0.100 4.62 × 10−3 0.210
O94779 CNTN5 0.155 1.168 0.061 1.24 × 10−2 0.377
P12544 GZMA 0.129 1.138 0.059 2.88 × 10−2 0.598
O14594 NCAN 0.183 1.201 0.088 3.93 × 10−2 0.598
O14793 GDF-8 0.095 1.100 0.047 4.42 × 10−2 0.598
Q16775 HAGH 0.147 1.158 0.074 4.60 × 10−2 0.598
APOE4 stratum
P55285 CDH6 0.638 1.893 0.171 3.33 × 10−4 0.030
Q16775 HAGH 0.481 1.618 0.138 7.20 × 10−4 0.033
Q92752 TN-R 0.280 1.323 0.094 3.72 × 10−3 0.113
P01138 Beta-NGF 0.431 1.539 0.182 2.00 × 10−2 0.340
Q8NFP4 MDGA1 0.164 1.178 0.070 2.22 × 10−2 0.340
P57087 JAM-B 0.318 1.374 0.137 2.24 × 10−2 0.340
P41217 CD200 0.335 1.398 0.155 3.31 × 10−2 0.394
Q9BS40 LXN 0.619 1.857 0.292 3.67 × 10−2 0.394
P16234 PDGF-R-alpha 0.324 1.383 0.159 4.42 × 10−2 0.394
Q6ISS4 LAIR-2 0.107 1.113 0.053 4.84 × 10−2 0.394
APOE33 stratum
Q2VWP7 PRTG 0.309 1.362 0.122 1.22 × 10−2 0.778
O94779 CNTN5 0.193 1.213 0.081 1.85 × 10−2 0.778
O14594 NCAN 0.248 1.281 0.110 2.57 × 10−2 0.778
P55285 CDH6 0.202 1.224 0.150 1.79 × 10−1 0.842
Q16775 HAGH −0.018 0.982 0.092 8.42 × 10−1 0.957
APOE2 stratum
P17405 SMPD1 −0.447 0.640 0.203 3.51 × 10−2 0.966
Q2TAL6 VWC2 −0.362 0.696 0.166 3.69 × 10−2 0.966
Q16775 HAGH 0.482 1.619 0.227 4.25 × 10−2 0.966
P55285 CDH6 0.498 1.645 0.324 1.35 × 10−1 0.966
Table 1. Results of plasma-based proteome association with Alzheimer’s disease. Abbreviations: β, regression 
coefficient; OR, odds ratio; SE, standard error; APOE, apolipoprotein E; FDR, False discovery rate. Note: 
Multiple testing correction by false discovery rate (FDR) < 0.05 was considered significant.
4Scientific RepoRtS |         (2020) 10:8233  | https://doi.org/10.1038/s41598-020-65038-5
www.nature.com/scientificreportswww.nature.com/scientificreports/
levels. All genome-wide significant pQTLs are located in the intergenic region at 5′ UTR region of the CDH6 
gene. Among the 13 identified pQTLs, rs111283466 was the lead pQTL with the effect estimate (β) of 1.068 and 
P-value 1.92 × 10−9 (Supplementary Table 8). Q-Q plot (Supplementary Fig. 5a) indicates that the results are well 
adjusted for population stratification (λ = 1.0056). Further lookups in the GTEx database showed that the lead 
pQTL (rs111283466) also affects the expression of CDH6 gene in various body tissues. GWAS analysis of HAGH 
protein levels did not identify any genome-wide significant pQTLs. Manhattan plot and Q-Q plot for GWAS 
results of HAGH protein levels are provided in the Supplementary materials (Supplementary Figs. 4 and 5b).
Discussion
In our study, plasma levels of CDH6 and HAGH proteins are significantly increased in presymptomatic AD 
patients compared to controls in the APOE4 stratum. In the replication analysis, both CDH6 and HAGH pro-
teins showed significant association with AD in the BioFINDER study in APOE ε4 carriers. CDH6 protein levels 
were significantly correlated with p-tau and t-tau measurements in CSF of the ADC. In GWAS analysis, we have 
also identified a genome-wide significant pQTL for CDH6 protein levels in the blood (rs111283466), which also 
affects the expression levels of CDH6 transcripts in several tissues.
We observed a significant increase of CDH6 protein levels in the plasma of presymptomatic AD cases carrying 
the APOE ε4 allele which was also replicated in the BioFINDER study. When comparing our findings to the other 
studies19–22, we do not have an overlap in understudy proteins. However, like previous studies we do find an effect 
of the APOE gene on plasma level of prorteins21,22. In the APOE4 stratum, we see that the volcano plot (Fig. 1) 
is clearly asymmetric suggesting increased levels of most neuronal proteins in AD patients carrying this allele 
before the clinical onset of disease. This might be explained by an increase in the blood-brain barrier permeabil-
ity in APOE ε4 carriers27, which may lead to increased levels of CDH6 in the blood as a result of higher levels of 
CDH6 in the brain. We found that CDH6 levels in the blood are driven by a genetic variant (rs111283466) in the 
cis-regulatory region. This may determine the CDH6 levels in both brain and blood cells, leaving the possibility 
open that elevated CDH6 has a blood-derived origin. Yet, such a mechanism does not explain why elevated levels 
Figure 1. Volcano plots representing the association of plasma protein levels with Alzheimer’s disease (AD) 
in (a) overall analysis; (b) APOE4 stratum; (c) APOE33 stratum and (d) APOE2 stratum. Each dot represents a 
protein with regression coefficient (β) of association plotted on x-axis and -log10 of P-values on y-axis. Proteins 
showing nominal association (P-value < 0.05) are annotated in overall and stratified analysis. Light blue color 
of dot indicates decreased protein levels with β −0.0 to −0.184 and dark blue to indicate with β < −0.184 while 
pink color indicates increased protein levels with β ranging from 0.0 to 0.184 and red color shows β > 0.184. 
Black dots are used for proteins which pass the multiple testing (false discovery rate <0.05).
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in the blood are only seen in patients carrying the APOE ε4 allele. It is of note that the CDH6 coding gene is part of 
a larger cluster of cadherin (CDH) genes including CDH9, CDH10, CDH12 and CDH18. As all of the CDH genes 
are paralogues and share homology, it is crucial to exclude cross-reactions of the antibodies28 used by Olink across 
CDH proteins. Our GWAS benchmarks that the protein assessed in our plasma is indeed CDH6, as we found 
that the most important driver of the protein is in the promoter region of CDH6. None of the recently published 
GWAS of proteins reported significant pQTLs for CDH6 protein based on SomaLogic29,30. The aptomere based 
measurement of the SomaLogic yields a different protein spectrum than that of the antibody-based method of 
Olink31. Our identified pQTLs did not show any association with AD (P-value < 0.05) in the largest AD GWAS11. 
However, we find in our study that levels of CDH6 were increased in APOE ε4 carriers compared to APOE ε2 
carriers. We do find that the region is associated to postcentral gyri in GWAS32 and a study has reported reduced 
volume of postcentral gyri in dementia patients33.
Interestingly, we found significant positive associations of CSF levels of CDH6 protein with p-tau and t-tau 
levels in overall as well as in AD and controls only analyses, which are considered as biomarkers of neuronal 
injury and tau pathology34,35. The upregulation of CDH6 protein in cerebral cortices of AD mice models (APP/
PS1) compared to wild type has been reported by Lu et al.36, which is in line with our observation of positive cor-
relation between CDH6 levels and AD pathological markers in CSF. Yet, we did not observe an association of the 
CDH6 protein with AD in CSF. We also observed positive association between CDH6 levels with amyloid-beta 
42 in CSF of the controls, which might indicate disturbance in the amyloid-beta 42 metabolism which precedes 
decades before the buildup of Aβ in the brain37. Alternatively, it may point towards a similar mechanism of pro-
duction of the Aβ-42 and CDH6 proteins in a healthy state38. Increased levels of phosphorylated CDH6 protein 
levels were reported upon the addition of amyloid-beta in cortical neuronal cells39, which adds evidence to the 
role of CDH6 in AD pathology. Taken together, these findings suggest that CSF levels of CDH6 protein may be 
associated with neuronal and axonal cell injury and neurofibrillary tangles in AD.
CDH6 is a cell surface glycoprotein that belongs to type II cadherin’s40. Cadherins are highly expressed in the 
brain and other tissues. They strongly interact with other molecules to perform molecular processes including 
synaptic functions41–43, synaptogenesis44, TGF-B signaling45, neural crest differentiation46, presenilin-mediated 
signaling and integrity of blood-brain barrier47. Although it is not possible to infer whether the correlation of 
AD pathology with CDH6 in plasma and CSF, are cause or consequence of the disease, several pieces of evidence 
favor the role of CDH6 in the pathogenesis of AD39,48. A recent study showed that the ADAM10 enzyme, whose 
coding gene is associated with AD11, is involved in proteolytic cleavage of the CDH6 protein, resulting in the for-
mation of C-terminal fragment49, in a similar manner as it cleaves the amyloid precursor protein (APP)50,51. The 
Biomarkers*
Overall APOE4 stratum APOE33 stratum APOE2 stratum
β SE P-value β SE P-value β SE P-value β SE P-value
CDH6 1.212 0.349 5.18 × 10−4 1.365 0.474 3.97 × 10−3 0.961 0.585 1.01 × 10−1 2.612 3.210 4.16 × 10−1
HAGH 0.631 0.081 7.56 × 10−15 0.506 0.103 9.31 × 10−7 0.739 0.145 3.76 × 10−7 5.565 3.979 1.62 × 10−1
Table 2. Association of plasma levels of CDH6 and HAGH proteins with Alzheimer’s disease in the BioFINDER 
Study. Abbreviations: AD, Alzheimer’s disease; β, regression coefficient; SE, standard error. *Logistic regression 
analysis adjusting for age, sex and date of sample collection.
Figure 2. Venn diagram showing the overlap of proteins identified in the association analysis results of overall 
and APOE stratified discovery analysis.
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transmembrane N-cadherin (CDH2), a paralogue of CDH6 and functionally related to CDH643, is also known to 
be cleaved by ADAM10 into N-cadherin C-terminal fragment 1 (NcadCTF1). Andreyeva et al.52, have demon-
strated that NcadCTF1 leads to accelerated amyloid-β-induced synaptic impairment, a process that characterizes 
an early stage event in AD53,54. Increased levels of NcadCTF1 were also found in postmortem AD brain tissues 
compared with controls, suggesting that cadherins might induce synaptic dysfunction in a synergistic manner52.
In addition to CDH6, increased plasma levels of HAGH (Hydroxyacylglutathione hydrolase, mitochondrial) 
protein also showed significant association with AD in those who carry the APOE ε4 variant and suggestive 
association in overall and in APOE ε2 carriers. This finding is in line with the recently published findings of the 
BioFINDER study25 and further supported by the APOE stratified analysis in the BioFINDER study that was 
conducted for the present study. In the replication analysis, plasma levels of HAGH showed significant associa-
tion in both APOE ε4 and APOE ε33 carriers while in the discovery analysis in the Rotterdam Study HAGH only 
showed significant association in APOE ε4 carriers which may be due to the lack of power. The HAGH protein is 
also known as glyoxalase-2, an enzyme, which is involved in the glyoxalase system along with glyoxalase-1 and its 
cofactor glutathione, a key player is oxidative stress control55,56. Overall, the glyoxalase system is involved in the 
detoxification of glycolysis by-products particularly cytotoxic metabolite methylglyoxal57. Levels of methylglyoxal 
in plasma are elevated during various disease conditions including hyperglycemia, which leads to the formation 
of reactive oxygen species (ROS) and causes oxidative stress. Moreover, methylglyoxal is also the precursor of 
glycation end products (AGEs) which are implicated in neurodegeneration and AD58,59. The most compelling 
evidence for the role of the glyoxalase-2 protein in AD is that the AGEs and glyoxalase system is implicated in the 
regulation of amyloid precursor protein (APP) expression60,61. Although glyoxalase system attributes protection 
against methylglyoxal mediated oxidative stress, earlier studies have also observed increased levels of glyoxalase-1 
enzyme (involved in the first step of methylglyoxal detoxification) in early AD stages62,63. Increased levels of 
glyoxalase-2 (involved in the second step of methylglyoxal detoxification) in plasma might be a compensatory 
mechanism to increased levels of methylglyoxal during the early phase of disease or a general stress response55. 
The growing number of studies have suggested the involvement of oxidative stress during the prodromal stage 
of AD64–66, which is in line with our finding of increased levels of glyoxalase-2 observed before the onset of AD.
The strength of the current study includes that it is conducted in the prospective population-based RS cohort, 
where samples were selected with mean 6.9 years of follow-up preceding the diagnosis of AD. It allowed us to 
study the plasma proteomics changes prior to the development of AD clinical symptoms. As AD is a disorder 
of the brain, we have validated that CSF levels of CDH6 are also associated with biomarkers of AD in CSF in an 
independent cohort. Further, we used the Olink neurology proteomic panel of 91 proteins for the quantification 
of proteins in the plasma, which estimates targeted proteins expressed in the brain from different pathways. One 
of the major limitations of our study is the limited sample size, including a small number of APOE ε4 carrier 
controls in the stratified analysis.
Biomarkers*
Overall APOE4 stratum APOE33 stratum APOE2 stratum
β SE P-value β SE P-value β SE P-value β SE P-value
Aβ-42 16.574 26.827 5.37 × 10−1 33.701 35.001 3.37 × 10−1 14.499 44.966 7.48 × 10−1 −103.767 69.354 1.45 × 10−1
p-tau 23.189 3.404 3.48 × 10−11 26.674 5.781 8.36 × 10−6 21.981 5.564 1.17 × 10−4 25.663 7.697 2.29 × 10−3
T-tau 207.396 36.437 2.40 × 10−8 235.009 59.158 1.10 × 10−4 193.859 64.068 2.90 × 10−3 298.437 86.637 1.66 × 10−3
Table 3. Association of CSF based CDH6 protein levels with AD biomarkers in Amsterdam Dementia Cohort. 
Abbreviations: AD, Alzheimer’s disease; β, regression coefficient; SE, standard error. *Linear regression analysis 
adjusting for age and sex.
Figure 3. Correlation plot between cerebrospinal fluid (CSF) levels of CDH6 with Aβ−42, p-tau and t-tau.
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In conclusion, we observed elevated protein levels of CDH6 in plasma of AD patients carrying APOE ε4 allele 
in the discovery and replication analysis, a protein that plays a role in synaptogenesis. Positive correlation of 
CSF CDH6 levels with p-tau and t-tau may also indicate the association of CDH6 with neurodegeneration. We 
further found the association of the plasma levels of HAGH protein to AD in those carrying the APOE ε4 allele. 
Association of HAGH with AD further suggest the involvement of the glyoxalase and oxidative stress pathways 
in the pathogenesis of AD.
Methods
Study populations. Rotterdam study. The Rotterdam Study (RS) is a prospective population-based study 
comprising of 14,926 middle and older aged (≥45 years) individuals from the Ommoord district of Rotterdam. 
The RS consists of three cohorts including RS-I (started in 1990, N = 7983 participants), RS-II (started in 2000, 
N = 3011) and RS-III (started in 2006, N = 3932)67. Study participants were extensively interviewed and physi-
cally examined at baseline and after every 3 to 4 years. For each participant fasting blood was collected at a dedi-
cated center, centrifuged (Speed = 3500 g for 20 min at 4 °C) within 4 hours of venipuncture to collect plasma and 
stored at −80 °C. The study has been approved by the Medical Ethical Committee of Erasmus Medical Center and 
by the Ministry of Health, Welfare and Sport of the Netherlands. Written informed consent was obtained from 
each study participant to participate and to collect information from their treating physicians. All methods were 
performed in accordance with the relevant guidelines and regulations. In current nested case-control proteomics 
analysis, we chose 161 incident AD cases and 155 controls match with respect to their age and sex, from the fifth 
visit of RS-I (RS-I-5) cohort. Table 4 shows the baseline characteristics of the selected sample. There were no sig-
nificant differences in age, sex and body mass index (BMI). AD patients were more often carriers of the APOE ε4 
variant and less often of the APOE ε2 variant. Blood for the proteome profiling was collected on average 6.9 years 
(standard deviation [SD] = 1.7) before the onset of clinical dementia in patients and mean 8.7 years (SD = 3.2) 
before the latest follow-up in controls.
Dementia diagnosis. Over time, all participants were screened for dementia using the Mini-Mental State 
Examination (MMSE)68 and Geriatric Mental Schedule (GMS)69 organic level for all participants. Screen-positive 
subjects (MMSE < 26 or GMS organic level > 0) underwent the Cambridge examination for mental disorders 
of the elderly (CAMDEX)70 and participants suspected of having dementia were extensively examined with 
neuropsychological testing and neuroimaging biomarkers when available. Patients were further ascertained by 
linking them with their medical records from general practitioners, the regional institute for outpatient men-
tal health care and municipality. Dementia of all patients was diagnosed based on the internationally accepted 
Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R) criteria and AD using the National Institute 
of Neurological Disorders and Stroke–Association Internationale pour la Recherche et l’Enseignement en 
Neurosciences (NINCDS-ADRDA)71 criteria for possible, probable and definite AD. NINCDS-ADRDA crite-
ria were also used to diagnose vascular dementia. The final diagnosis was confirmed by a panel of neurolo-
gists, neurophysiologists, and research physicians72. AD diagnosis in RS is also provided in more detail in earlier 
publications72.
Proteome profiling. Proteomics profiling of the 316 plasma samples was performed using neurology panel 
of OLINK’s Proximity Extension Assay (ProSeek, OLINK AB, Uppsala, Sweden), which includes 91 proteins 
involved in various pathways including axon development, axon guidance, cell adhesion, cell death, cell dif-
ferentiation, cell growth, cellular metabolic process, immune response, MAPK cascade, neurogenesis, prote-
olysis, signal transduction and synapse assembly (https://www.olink.com/products/neurology/). This method 
uses affinity-based assay, in which a pair of oligonucleotide-labeled antibody probes bind to a target protein. 







Age (SD) blood 
collection, years 77.16 (5.39) 77.43 (5.21) 76.89 (5.59)
Age at onset/last 
follow-up (SD) 84.99 (5.33) 84.37 (5.01) 85.63 (5.56)
Female (%) 201 (63%) 104 (65%) 97 (63%)
Body Mass 
index (SD) 27.32 (4.10) 27.29 (3.75) 27.37 (4.46)
Follow-up (SD) 
years 7.82 (2.71) 6.94 (1.71) 8.74 (3.22)
APOE genotype
APOE 44/34/24 98 68 30
APOE 33 171 76 95
APOE 22/23 34 13 21
Table 4. Population descriptive of the Rotterdam Study. Abbreviations: AD, Alzheimer’s disease, SD, Standard 
deviation, APOE, apolipoprotein E gene.
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between two probes bound in close proximity. The generated PCR target sequence is detected and quanti-
fied using real-time PCR method. The resultant protein abundance is provided as NPX (Normalized Protein 
Expression), which is an arbitrary unit on log2 scale. Lower limit of detection is estimated based on negative 
controls inserted in each run and measurements below this limited were treated as missing. None of the detected 
markers in our dataset reach missingness more than 10 percent. Protein markers with missing values less than 
10% were imputed with the lowest detected limit for further analysis. More detailed information about detection 
limits, assay performance and validation methods are available from the service provider (www.olink.com)73.
APOE genotyping. In the RS APOE genotyping was performed using Polymerase chain reaction (PCR) and 
amplified PCR product was digested with HhaI enzyme. Restriction fragments of enzyme products were vis-
ualized by silver staining after getting them separated with precast ExcelGel gels (Pharmacia Biotech, Uppsala, 
Sweden). Genotype results were examined by three independent persons. In the case of non-agreement APOE 
genotype was repeated74,75.
Genotyping and imputations. In the RS participant’s blood was collected during baseline and follow-up visit. 
DNA genotyping was performed for all the participants with proper DNA quality with the 550 K, 550 K duo, or 
610 K Illumina arrays. In genotyping quality control, genetic variants exclusion criteria include, call rate <95%, 
Hardy-Weinberg equilibrium P < 1.0 × 10−6 and Minor Allele Frequency (MAF) < 1%. Sample exclusion cri-
teria include excess autosomal heterozygosity (0.336), call rate <97.5%, duplicate or family relationships and 
ethnic outliers identified by the identity-by-state clustering analysis (having identity-by-state probability <97% 
or>3 standard deviation from population mean)76. Further, genetic variants were imputed with the Haplotype 
Reference Consortium (HRC) reference panel (version 1.0)77, using the Michigan imputation server78. The server 
uses SHAPEIT2 (v2.r790)79 to phase the genotype data and performs imputation with Minimac 3 software80. 
Genotyping information was available for 281 among 316 participants included in the current study.
BioFINDER study. In the current study, replication analysis was performed in 671 participants (AD patients 
= 186, Controls = 485) of the BioFINDER (Biomarkers For Identifying Neurodegenerative Disorders Early and 
Reliably) study. Characteristics of the BioFINDER study participants included in the replication analysis are pro-
vided in Supplementary Table 9. The BioFINDER study includes participants from southern Sweden recruited 
between 2009 and 2014 (www.biofinder.se). The study participants were assessed by experienced physicians 
including the neurological, psychiatric and cognitive assessments81. The NINCDS-ADRDA criteria were used 
to classify Alzheimer’s disease dementia patients for probable Alzheimer’s disease patients. All dementia due to 
Alzheimer’s disease patients had pathological CSF Aβ42/Aβ40 ratio of <0.1. The inclusion criteria for the cogni-
tively normal elderly participants included (i) aged 60–80 years, (ii) MMSE scores ranging between 28–30 at their 
baseline screening visit, (iii) no cognitive impairment symptoms assessed by a physician, and (iv) not fulfilling the 
criteria for mild cognitive impairment or dementia. Exclusion criteria included (i) refused lumbar puncture, (ii) 
significant neurological or psychiatric disease, (iii) current alcohol or substance misuse, or (iv) systematic illness 
preventing them from participating in the study25,81. Written Informed consents were collected from each study 
participant and the study has been approved by the Regional Ethics Committee in Lund, Sweden.
Protein profiling. During the baseline visit of the BioFINDER study, plasma and lumbar CSF samples were col-
lected from non-fasting participants. Standardized protocol was followed to analyze the plasma and CSF samples. 
All samples were centrifuged at 2000 g (+4 °C for 10 min), and aliquoted into 1 ml polypropylene tubes (Sarstedt 
AG & Co., Nümbrecht, Germany), and stored at −80 °C. Before the proteomics profiling, plasma and CSF sam-
ples underwent one cycle of freeze-thaw, and further aliquoted into 200 L Lobind tubes (Eppendorf Nordic A/S, 
Denmark). Protein concentrations were quantified using the ProSeek multiplex immunoassay, developed by 
Olink Proteomics (Uppsala, Sweden)25.
Amsterdam dementia cohort (ADC). In the validation analysis of most interesting proteins, we used 441 
participants from the ADC cohort whose CSF samples were already profiled for neurology related proteins using 
the OLINK’s Proximity Extension Assay (ProSeek, OLINK AB, Uppsala, Sweden). Information about character-
istics of patients included in current analysis as a part of the validation dataset is listed in Supplementary Table 10.
The ADC is a prospective memory-clinic cohort that was established in September 2000 at the Alzheimer 
Center Amsterdam of Amsterdam UMC. The cohort has included 6000 individuals until September 201782,83. 
All participants underwent standardized cognitive screening including neurological and cognitive examination, 
blood sampling, a lumbar puncture to collect CSF and brain magnetic resonance imaging. All CSF samples were 
stored in agreement with the JPND-BIOMARKAPD guidelines84. All subjects provided written informed consent 
for use of biomaterial and clinical data for research and the study was approved by the local medical ethical review 
board. All methods were performed in accordance with the relevant guidelines and regulations. A sample of 441 
participants selected for our validation analysis consists of 242 AD and 199 cognitively normal controls who were 
presented at the memory clinic with subjective cognitive decline (i.e., Criteria for mild cognitive impairment and 
dementia not fulfilled)). As additional inclusion criteria, controls were required to have normal AD CSF biomark-
ers profile: low CSF β-amyloid 1–42 (Aβ42) and high p- or t-tau level (applying local laboratory cut-offs) and to 
remain cognitively stable for 2 years. All participants underwent standard neurological and cognitive assessments 
and the diagnosis was assigned according to consensus AD criteria83. Global Mini-Mental State Examination 
(MMSE) was used to examine global cognition. The levels of CSF AD-related biomarkers (Aβ42, total and phos-
phorylated tau [t-Tau and p-Tau181]) were analyzed at Amsterdam UMC as part of the routine diagnostic pro-
cedure using commercially available kits (Innotest Aβ(1-42), total Tau, phospho-Tau(181 P); Fujirebio, Ghent, 
Belgium)10,24.
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Statistical analysis. Plasma protein association with AD. To identify AD-associated proteins, plasma lev-
els of 91 proteins were compared between incident AD cases and non-demented controls using logistic regres-
sion, adjusted for age and sex in the first model. In the second model, we additionally adjusted for body mass 
index (BMI), smoking, educational status and medication use (lipid-lowering medications, antihypertensive and 
anti-inflammatory medication). To identify APOE specific associations of proteins with AD, we performed strat-
ified association analysis based on APOE genotype carrier status. All participants were divided into APOE4 stra-
tum (APOE 44/34/24), APOE3 stratum (APOE 33) and APOE2 stratum (APOE 22/23). Participants with APOE 24 
genotypes were pooled within the APOE4 stratum because an earlier study has demonstrated that the risk profiles 
of APOE 24 genotype to AD and dementia is similar to those with APOE 34 genotype carriers5. The association 
results were corrected for multiple testing using false discovery rate (FDR) by Benjamini and Hochberg method 
separately for the overall analysis, and in each APOE stratum85 and association tests with FDR < 0.05 were con-
sidered significant. All analyses were performed using R software (https://www.r-project.org).
Sensitivity analyses. Moreover, we performed sensitivity analyses. In the first sensitivity analysis, we repeated 
the overall and APOE stratified regression analysis (Model 1: age and sex) additionally adjusting for the follow-up 
time (the time between blood collection and onset of AD or last follow-up for controls). In the second sensitivity 
analysis, to assess the differential bias due to missingness, we performed the overall and APOE stratified asso-
ciation analysis in the non-imputed proteomics data adjusting for age and sex. We also tested the interaction of 
APOE genotype (ε4 carriers and non-carriers) and proteins levels using logistic regression model adjusting for 
age and sex.
Figure 4. Flowchart of the analyses. Rotterdam Study was used as discovery cohort in plasma-based proteomics 
analysis. Altered proteins in plasma analysis were replicated in the BioFINDER study and further validated in 
Amsterdam Dementia Cohort participants. Abbreviations; AD: Alzheimer’s disease; APOE: apolipoprotein E; 
GWAS: genome-wide association study; CSF: cerebrospinal fluid.
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Additional analysis of proteins showing association with AD. A detailed flowchart of the analysis is provided 
in Fig. 4 about the discovery, replication and validation analysis. Proteins that appeared significantly altered in 
overall or APOE stratified analysis were further tested for association with APOE genotypes; second GWAS was 
performed to identify pQTLs, regulating the levels of protein in blood.
Replication analysis. Replication analysis of two proteins was performed in an independent BioFINDER study. 
We performed association of plasma levels of proteins with AD versus controls (AD cases = 186, controls = 485) 
in the overall sample and stratified by APOE genotype: APOE4 stratum (APOE 44/34), APOE33 stratum (APOE 
33) and APOE2 stratum (APOE 22/23). We used logistic regression analysis adjusted for age, sex and date of 
sample collection.
Validation analysis: Association of CSF protein levels with Aβ-42, p-tau, and t-tau. In the validation analysis of 
specific proteins in an independent ADC cohort (N = 441), we performed association of CSF protein levels with 
AD versus control group and with Aβ-42, p-tau and t-tau levels in CSF. All the validation analyses were per-
formed in the overall sample and stratified by APOE genotype: APOE4 stratum (APOE 44/34), APOE33 stratum 
(APOE 33) and APOE2 stratum (APOE 22/23). We used linear regression analysis adjusted for age and sex to 
evaluate the association of proteins measured in CSF with AD brain pathology biomarkers in the overall sample 
and stratified by clinical diagnosis (AD and controls).
Association of plasma protein levels with APOE genotype. To further evaluate the association of proteins with 
APOE genotypes, we compared protein levels, among APOE genotype groups (APOE 44/34/24 = 1 versus APOE 
33 = 0, APOE 44/34 = 1 versus APOE 22/23 = 0 and APOE 22/23 = 1 versus APOE 33 = 0) in the overall study 
sample, in AD patients, and in control groups separately. Linear regression analysis was performed using protein 
levels as outcome and APOE status as predictor, adjusted for age and sex.
Genome-wide association study. Further, we performed the genome-wide association study (GWAS) to identify 
protein quantitative trait loci (pQTLs) for candidate proteins. We regressed out protein levels against age, sex 
and principal components to calculate residuals. To normalize the calculated residuals we applied Rank-inverse 
transformation on residuals. Principal components derived from genotypes were used in the association analysis 
to adjust for population stratification. GWAS of rank-inverse normalized residuals was performed using score 
test option in RVTEST software86. Variants with low imputation quality R-squared <0.3 and minor allele count 
less than five were excluded from the results. Manhattan and quantile-quantile (Q-Q) plots for GWAS results 
were generated with web-based utility Functional mapping and annotation of genetic associations (FUMA)87 
and regional association plots using LocusZoom (http://locuszoom.org). pQTLs with a P-value < 2.5  × 10−8 
(5 × 10−8/2 tested proteins) were considered genome-wide significant. To check the overlap of identified pQTL 
with expression quantitative loci (eQTLs) we used GTEx data base88.
Data availability
Current study used data from RS and ADC, where sharing of participants data is not allowed publicly due to 
legal and ethical permissions. Informed consents collected for both studies do not allow to share individual 
participants data in public repository. Data access can be made available for interested researchers upon request 
to corresponding author Cornelia M. van Duijn (Cornelia.vanDuijn@ndph.ox.ac.uk).
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